Published 20 May 2009, doi:10.1136/bmj.b1451
Cite this as: BMJ 2009;338:b1451

Endgames

Picture Quiz

A characteristic rash

E E Craythorne, specialist registrar, S Wong, specialist registrar, R Morris Jones, consultant, A W P du Vivier, consultant

1 Department of Dermatology, King’s College Hospital, London SE5 9RS

Correspondence to: E E Craythorne emma_craythorne{at}hotmail.com

A 53 year old man presented with an itchy, red rash on his lower leg after a trip to Brazil. He recalled having been bitten on the right ankle while on a beach and had covered the bite with a plaster. The initial bite mark on the ankle extended by 1-2 cm per day in a serpiginous pattern across the ankle and up the leg (figure)Go. Other than intense irritation of the skin, he had no other symptoms and was systemically well.


Figure 1
View larger version (91K):
[in this window]
[in a new window]
[PowerPoint Slide for Teaching]
 
An itchy rash

 

Questions

1 What is the diagnosis?
2 What are the differential diagnoses?
3 How is it treated?

Answers

Short answers

1 Cutaneous larva migrans is a common, tropically acquired dermatosis caused by the percutaneous penetration and migration of larvae of nematode parasites.
2 Other infestations—including erythema migrans of Lyme disease, migratory myiasis, and larva currens caused by Strongyloides stercoralis—should be considered.
3 Cutaneous larva migrans is self limiting, but its clinical course is shortened by effective treatment with topical and oral anthelmintics such as albendazole, thiabendazole, and ivermectin.

Long answers
Cutaneous larva migrans is one of the most common imported parasitic infestations diagnosed in travel clinics1 and to be considered in the returned traveller.2 3 It is a parasitic skin infection caused by hookworm larvae which parasitise cats and dogs but may also penetrate into the epidermis of humans.4 It is most commonly, but not exclusively, found in the tropical and subtropical areas as well as the southwestern United States, and is usually associated with outdoor activities that include exposure to contaminated water or soil in such areas.

In Brazil, cutaneous larva migrans is highly endemic in resource poor communities: in Fortaleza, a capital city in the northeast, a 2003 study reported a prevalence of 3%,5 and a further study showed that less than 1% of travellers to northeast Brazil acquired cutaneous larva migrans during an average two week stay.6

Many different species of hookworm may cause cutaneous larva migrans, the commonest of which are listed in the box. The lifecycle of the parasite starts when eggs are passed from infected animal faeces into warm water or moist soil, where the larvae hatch. The larvae use various proteolytic enzymes to penetrate the stratum corneum before migrating. In human hosts, the larvae lack the collagenase enzymes required to traverse the basement membrane into the dermis, so the infection is confined to the skin in humans (other animal hosts have systemic manifestations).


Hookworms causing cutaneous larva migrans
Ankylostoma braziliense—found in Wild and domestic dogs and cats in central and southern United States
Uncinaria stenocephala—found in dogs in the Caribbean
Ankylostoma caninum—found in dogs in Europe
Bunostomum phlebotomum—found in cattle in Australia


Cutaneous larva migrans often starts as a tingling or pricking sensation at the site of penetration, usually within 30 minutes of the larva breaching the skin. As the larvae migrate they cause a highly pruritic, advancing, serpiginous eruption. The lesion is erythematous, 2-3 mm wide, and often palpable, extending at a rate of 1-2 cm per day. For this reason it is also known as the creeping eruption. Oedematous papules and vesicles may be additional features, and secondary staphylococcal or streptococcal infection can complicate this parasitic infection. Lesions typically affect the feet and toes, but also the anogenital region, buttocks, breasts, hands, and knees—any area of skin likely to be in contact with contaminated sand. Systemic features, although not common, include peripheral eosinophilia, migratory pulmonary infiltrates, and raised concentrations of IgE.7

The diagnosis is based on the appearance of the rash and relevant travel history (the rash is often seen in patients who have been lying, sitting, or walking on a beach). A skin biopsy is not usually necessary but may show a superficial, eosinophil rich, chronic inflammatory infiltrate with spongiosis and necrotic keratinocytes. Larvae positive on periodic acid Schiff (PAS) staining can be seen on skin biopsy.

The condition is benign and self limiting. As human hosts do not support the lifecycle of the parasite, the larvae eventually die and the rash resolves within 4-8 weeks without treatment, depending on the species. The condition is highly treatable with anthelmintics, which shorten the course of the disease and relieve symptoms. The treatment of choice in localised disease is topical thiabendazole (15% in a hygroscopic base) for five days.8 Oral albendazole 400 mg a day for three days or thiabendazole or ivermectin 200 µg/kg in a single dose are used when topical treatment fails or in more florid cases. The prognosis is good, and with treatment the lesions resolve within a week or two.

Measures to prevent cutaneous larva migrans infection are also relevant, and travellers should be aware of the condition. Avoiding direct contact with sand is especially important, particularly in areas protected from tidal movement or intense sunlight, where the larvae are most likely to survive.7


Learning points
  • Cutaneous larva migrans (CLM) is one of the most common imported parasitic infestations diagnosed in travel clinics
  • It is benign and usually self limiting within 4-8 weeks
  • Treatment of choice is with topical thiobendazole in early disease
  • Many travellers are unaware of the condition and therefore do not take precautions to avoid infection


Cite this as: BMJ 2009;338:b1451


Competing interests: None declared.

Provenance and peer review: Commissioned; externally peer reviewed.

Patient consent obtained.

References

  1. Freedman DO, Weld LH, Kozarsky PE, Fisk T, Robins R, von Sonnenburg F,et al. Spectrum of disease and relation to place of exposure among ill travellers. N Engl J Med 2006;354:119-30.[Abstract/Free Full Text]
  2. Lederman ER, Weld LH, Elyazar IR, von Sonnenburg F, Loutan L, Schwartz E, et al. Dermatologic conditions of the ill returned traveler: an analysis from the GeoSentinel Surveillance Network. Int J Infect Dis 2008;593:602.
  3. Recent developments in dermatological syndromes in returning travelers. Curr Opin Infect Dis 2008;21:495.[CrossRef][Web of Science][Medline]
  4. Heukelbach J, Menke N, Feldmeier H. Cutaneous larva migrans and tungiasis: the challenge to control zoonotic ectoparasitoses. Trop Med Int Health 2002;7:907-10.[CrossRef][Web of Science][Medline]
  5. Heukelbach J, Wilcke T, Meier A, Moura RCS, Feldmeier H. A longitudinal study on cutaneous larva migrans in an impoverished Brazilian township. Travel Med Infect Dis 2003;1:213-8.[CrossRef][Medline]
  6. Heukelbach J, Gomide M, Araújo F Jr, Pinto NS, Santana RD, Brito JR, et al. Cutaneous larva migrans and tungiasis in international travellers exiting Brazil: an airport survey. J Trav Med 2007;6:374-80.
  7. Blackwell V, Vega-Lopez F. Cutaneous larva migrans: clinical features and management of 44 cases presenting in the returning traveler. Br J Dermatol 2001;145:434-7.[CrossRef][Web of Science][Medline]
  8. Jelinek T, Maiwald H, Nothdurft HD, Löscher T. Cutaneous larva migrans in travelers: synopsis of histories, symptoms and treatment of 98 patients. Clin Infect Dis 1994;19:1062-6.[Web of Science][Medline]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Rapid Responses:

Read all Rapid Responses

The perils of sandbags
Grace Marshall
bmj.com, 28 May 2009 [Full text]



Access jobs at BMJ Careers
Whats new online at Student 

BMJ